Case Report: Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case Report
- 1 April 2006
- journal article
- case report
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 21 (2), 101-105
- https://doi.org/10.1089/cbr.2006.21.101
Abstract
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide—yttrium-90-ibritumomab tiuxetan—is described, as well as the subsequent steps taken to both address the occurrence and to prevent the reoccurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.Keywords
This publication has 23 references indexed in Scilit:
- Paravasation von Zytostatika: Prävention und TherapieDeutsche Medizinische Wochenschrift (1946), 2005
- Extravasation of systemic hemato-oncological therapiesAnnals of Oncology, 2004
- Radiation Safety Guidelines for Radioimmunotherapy With Yttrium 90 Ibritumomab TiuxetanClinical Journal of Oncology Nursing, 2004
- Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)Seminars in Nuclear Medicine, 2004
- Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)Seminars in Nuclear Medicine, 2004
- Monoclonal antibodies in the treatment of cancer, Part 2.American Journal of Health-System Pharmacy, 2003
- Monoclonal antibodies in the treatment of cancer, Part 1.American Journal of Health-System Pharmacy, 2003
- Skin necrosis from extravasation of Vinorelbine*Journal of the European Academy of Dermatology and Venereology, 2002
- Evaluation and treatment of chemotherapy extravasation injuriesJournal of Pediatric Oncology Nursing, 2000
- Radiation Accidents and Nuclear Energy: Medical Consequences and TherapyAnnals of Internal Medicine, 1988